Skip to content

Trial Summary

A Phase 1a/1b Dose Escalation and Expansion Study of SBP-101 in Combination with Nab-Paclitaxel and gemcitabine in subjects with previously untreated metastatic pancreatic ductal adenocarcinoma Previously Untreated Metastatic Pancreatic Ductal Adenocarcin



ACTRN/NCT /ethics:


Scientific title:

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Sponsor / Cooperative group:

Sun BioPharma Inc

Trial & Patient Characteristics

Cancer TypePancreas
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date2018-06-04
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Phone08 8292 2240
Principal InvestigatorDr Nimit Singhal
Recruitment StatusRecruiting